Background: Chronic low‑grade inflammation plays a central role in the development and progression of type 2 diabetes mellitus (T2DM). MicroRNAs (miRNAs) have emerged as promising regulators of inflammatory pathways and potential non‑invasive biomarkers for early disease detection. This study aimed to investigate the expression levels of miR‑20a‑5p and miR‑149‑5p and their association with pro‑inflammatory cytokines in individuals with T2DM, pre‑diabetes, and non-diabetics.
Methods: A total of 90 participants were enrolled and divided into three groups: non-diabetic (n=30), pre‑diabetic (n=30), and T2DM (n=30), according to the American Diabetes Association (ADA)’s criteria. Serum levels of miR‑20a‑5p and miR‑149‑5p were quantified using real‑time polymerase chain reaction (PCR). The expression levels and protein concentrations of inflammatory cytokines (IL‑6, IL‑1β, TGF‑β, and IFN‑γ) were assessed by real‑time PCR and enzyme-linked immunosorbent assay (ELISA), respectively. The receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic power of the selected miRNAs.
Results: The expression of miR‑20a‑5p was significantly upregulated in both pre‑diabetic and T2DM groups, whereas the expression of miR‑149‑5p was significantly downregulated in the T2DM group. ROC analysis revealed excellent diagnostic power of miR‑20a‑5p for distinguishing T2DM (AUC=0.985) and pre‑diabetics (AUC=0.895) from non-diabetic controls. Elevated expression and serum levels of IL‑6, IL‑1β, TGF‑β, and IFN‑γ were observed in pre‑diabetic and T2DM groups. miR‑20a‑5p showed a significant positive correlation with pro‑inflammatory cytokines (P<0.001). while miR‑149‑5p demonstrated a significant negative correlation (P<0.001).
Conclusion: The dysregulated expression of miR‑20a‑5p and miR‑149‑5p is closely associated with inflammatory responses in T2DM and pre‑diabetes. miR‑20a‑5p has higher diagnostic accuracy and may serve as a promising circulating biomarker for early detection of diabetes‑related metabolic and inflammatory alterations.
Erfan Babahoseinpour, Reza Heidari, Ali Shakerimoghaddam et al.· Journal of Translational Reg...· 0 citations
Osteoarthritis (OA) is a common degenerative joint disease characterized by pain, stiffness, progressive cartilage loss, and reduced mobility. Current treatments primarily aim to relieve symptoms rather than restore damaged cartilage, and durable regeneration of native hyaline cartilage remains a major clinical challenge. Extracellular Vesicles (EVs), particularly those derived from Mesenchymal Stem Cells (MSCs), have emerged as promising cell-free therapeutic platforms because of their ability to modulate inflammation, regulate chondrocyte activity, and influence extracellular matrix metabolism. However, EV heterogeneity, source-dependent variability, limited targeting efficiency, inconsistent cargo loading, and lack of standardized manufacturing protocols continue to restrict their clinical translation. This review summarizes recent advances in engineered EV-based strategies for OA and cartilage repair, including parental-cell preconditioning, genetic modification, surface functionalization, cargo loading, artificial EV platforms, and biomaterial-assisted delivery. Importantly, we distinguish between in vitro findings, preclinical animal studies, and early clinical evidence to provide a balanced assessment of translational readiness. We also discuss key regulatory and safety challenges, including GMP-compliant production, batch-to-batch variability, quality-control criteria, potency assays, scalability, biodistribution, and long-term safety. By integrating EV engineering with translational and regulatory perspectives, this review highlights the potential of engineered EVs as future disease-modifying tools for OA while emphasizing that their clinical efficacy and capacity to restore durable hyaline cartilage remain to be demonstrated in robust human studies.
Shayan Boozarjomehri Amnie, Sina Mahmoudian, Mahdi Ghorbani et al.· Avicenna journal of medical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.